Home › Compare › DVNHF vs ABBV
DVNHF yields 17421.60% · ABBV yields 3.09%● Live data
📍 DVNHF pulled ahead of the other in Year 1
Combined, DVNHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DVNHF + ABBV for your $10,000?
Frontier Services Group Limited, an investment holding company, provides aviation, logistics, security, insurance, and infrastructure related services. The company operates through Aviation and Logistics Business; Security, Insurance and Infrastructure Business; and Financial Market Information Business segments. It offers online financial market information. The company's security services include protective services and specialized training services; logistics services comprise engineering project logistics services and special logistics services, such as transportation of valuables; and infrastructure solutions include project planning, business consulting, investment and financing, engineering design, project implementation and operation, and support services. It also provides consultancy and freight forwarding services; finance, liability, property, and personnel insurance services; and healthcare and airport management services. The company serves the oil and gas, mining, finance, energy, and infrastructure industries, as well as organizations. It operates in Africa, Europe, the People's Republic of China, Mainland China, Hong Kong, southeast Asia, and the Middle East. The company was formerly known as DVN (Holdings) Limited and changed its name to Frontier Services Group Limited in March 2014. Frontier Services Group Limited is headquartered in Admiralty, Hong Kong.
Full DVNHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.